1. Scrip
  2. >>Business
  3. >>Deals

Paratek To Acquire Optinose, Expanding Portfolio Beyond Antibiotics

 
• By Joseph Haas

Paratek agrees to acquire Optinose in a “take-private” deal valued at $330m, adding chronic rhinosinusitis product Xhance to its antibiotic Nuzyra.

merger and acquisition business concepts, join company on puzzle pieces, 3d rendering
Paratek will acquire Optinose and CRS drug Xhance

Less than two years after being taken private by Gurnet Capital and Novo Holdings, Paratek Pharmaceuticals has agreed to a merger with Optinose that will expand its product portfolio beyond the antibiotic Nuzyra (omadacycline). The transaction unveiled on 20 March is valued at approximately $330m, although more than a third of the potential value is tied to commercial performance of Optinose’s Xhance.

Key Takeaways
  • Paratek will expand its portfolio to include chronic rhinosinusitis drug Xhance in a take-private merger with Optinose.
  • Xhance, indicated to treat CRS patients with or without nasal polyps, has a much larger patient base after a 2024 label expansion

Like its June 2023 acquisition, which included a contingent value right (CVR) connected to sales of Nuzyra, Paratek’s planned acquisition of Optinose includes a CVR and will delist the Yardley, PA-based specialty firm from the Nasdaq exchange

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Regeneron Sees 23andMe Buy As Complement To Genetics Platform

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

More from Therapy Areas

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.